Anti‐platelet therapy: ADP receptor antagonists

The P2Y12 receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis. Agents that act as antagonists at this receptor are thus likely to provide effective antithrombotic therapy, provided tha...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of clinical pharmacology Vol. 72; no. 4; pp. 647 - 657
Main Authors Wijeyeratne, Yanushi Dullewe, Heptinstall, Stan
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.10.2011
Blackwell Science Inc
Subjects
anti‐platelet
Blood Platelets - drug effects
cangrelor
clopidogrel
Haemostasis Themed Issue
Humans
P2Y12
platelet
Platelet Aggregation - drug effects
Platelet Aggregation Inhibitors - pharmacology
prasugrel
Purinergic P2Y Receptor Antagonists - pharmacology
Thrombosis - prevention & control
ticagrelor
Online AccessGet full text

Cover

Abstract The P2Y12 receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis. Agents that act as antagonists at this receptor are thus likely to provide effective antithrombotic therapy, provided that there are no adverse effects on haemostasis. Here we describe the ADP receptor antagonists that are available and in development. We also consider their mode of action and ask whether there are additional mechanisms through which they exert their inhibitory effects on platelet function.
AbstractList The P2Y12 receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis. Agents that act as antagonists at this receptor are thus likely to provide effective antithrombotic therapy, provided that there are no adverse effects on haemostasis. Here we describe the ADP receptor antagonists that are available and in development. We also consider their mode of action and ask whether there are additional mechanisms through which they exert their inhibitory effects on platelet function.
The P2Y 12 receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis. Agents that act as antagonists at this receptor are thus likely to provide effective antithrombotic therapy, provided that there are no adverse effects on haemostasis. Here we describe the ADP receptor antagonists that are available and in development. We also consider their mode of action and ask whether there are additional mechanisms through which they exert their inhibitory effects on platelet function.
The P2Y(12) receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis. Agents that act as antagonists at this receptor are thus likely to provide effective antithrombotic therapy, provided that there are no adverse effects on haemostasis. Here we describe the ADP receptor antagonists that are available and in development. We also consider their mode of action and ask whether there are additional mechanisms through which they exert their inhibitory effects on platelet function.
The P2Y(12) receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis. Agents that act as antagonists at this receptor are thus likely to provide effective antithrombotic therapy, provided that there are no adverse effects on haemostasis. Here we describe the ADP receptor antagonists that are available and in development. We also consider their mode of action and ask whether there are additional mechanisms through which they exert their inhibitory effects on platelet function.The P2Y(12) receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis. Agents that act as antagonists at this receptor are thus likely to provide effective antithrombotic therapy, provided that there are no adverse effects on haemostasis. Here we describe the ADP receptor antagonists that are available and in development. We also consider their mode of action and ask whether there are additional mechanisms through which they exert their inhibitory effects on platelet function.
Author Heptinstall, Stan
Wijeyeratne, Yanushi Dullewe
Author_xml – sequence: 1
  givenname: Yanushi Dullewe
  surname: Wijeyeratne
  fullname: Wijeyeratne, Yanushi Dullewe
– sequence: 2
  givenname: Stan
  surname: Heptinstall
  fullname: Heptinstall, Stan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/21518389$$D View this record in MEDLINE/PubMed
BookMark eNqNkc1uEzEUhS1URNPCK6DZsZrB167_kEBKQ_mRKtEFrC2Pc9M6mowH24FmxyP0GXkSZkgJsKs3tnSPv2Ofc0KO-tgjIRXQBsb1ct0Al6JmwETDKEBDuTGmuX1EZofBEZlRTmUtmIBjcpLzmlLgIMUTcsxAgObazAjM-xJ-_rgbOleww1KVG0xu2L2q5m-vqoQehxJT5frirmMfcslPyeOV6zI-u99PyZd3F58XH-rLT-8_LuaXtT9T3NRKSL7iXhjODCqupFpp5R0ikwo0KA7aUNMaAKmXDFxrPHLDjTStEGfLlp-SN3vusG03uPTYl-Q6O6SwcWlnowv2_0kfbux1_GZHstJSjIAX94AUv24xF7sJ2WPXuR7jNlutDSjJqB6Vz_-1Onj8iWkU6L3Ap5hzwtVBAtROjdi1nYK3U_B2asT-bsTe_v3G4aoPxZUQp0eH7iGA13vA99Dh7sHG9nxxNZ34L1NQpIQ
CitedBy_id crossref_primary_10_1021_acsptsci_2c00044
crossref_primary_10_3390_biom12020206
crossref_primary_10_1002_prp2_686
crossref_primary_10_1016_j_ihj_2015_12_022
crossref_primary_10_3904_kjim_2016_228
crossref_primary_10_1111_apha_13191
crossref_primary_10_1016_j_thromres_2018_08_022
crossref_primary_10_2174_1381612825666190925163347
crossref_primary_10_7759_cureus_43899
crossref_primary_10_1080_10406638_2022_2041679
crossref_primary_10_1016_j_rechem_2024_101446
crossref_primary_10_1002_14651858_CD012534_pub2
crossref_primary_10_1016_j_jacbts_2022_06_002
crossref_primary_10_1111_apha_13268
crossref_primary_10_7759_cureus_42058
crossref_primary_10_1007_s11886_019_1168_y
crossref_primary_10_1016_j_ymthe_2022_06_019
crossref_primary_10_3390_biomedicines11082234
crossref_primary_10_1007_s40883_022_00257_y
crossref_primary_10_1016_j_mpmed_2014_06_015
crossref_primary_10_1111_jvp_12301
crossref_primary_10_1007_s12672_024_01463_6
crossref_primary_10_2174_1570180819666220602090408
crossref_primary_10_1016_j_biopha_2023_115184
crossref_primary_10_1016_j_bmcl_2013_05_025
crossref_primary_10_1016_j_jcmgh_2021_12_012
crossref_primary_10_1080_09537104_2017_1356453
crossref_primary_10_3389_fphar_2024_1332468
crossref_primary_10_1139_cjc_2014_0429
crossref_primary_10_1155_2019_7125162
crossref_primary_10_7759_cureus_23718
crossref_primary_10_3109_09537104_2015_1049519
crossref_primary_10_1016_j_ejps_2016_11_004
crossref_primary_10_2217_pgs_2018_0082
crossref_primary_10_1212_WNL_0000000000004937
crossref_primary_10_1007_s40256_021_00465_x
crossref_primary_10_1097_HPC_0000000000000243
crossref_primary_10_3343_alm_2019_39_1_23
crossref_primary_10_1371_journal_pone_0097328
crossref_primary_10_1016_j_ica_2021_120609
crossref_primary_10_17721_1728_2748_2014_68_36_40
crossref_primary_10_1007_s11010_015_2620_y
crossref_primary_10_1002_14651858_CD012534
crossref_primary_10_1002_jca_21592
crossref_primary_10_1016_j_clinbiochem_2014_03_005
crossref_primary_10_1208_s12248_017_0116_2
crossref_primary_10_31083_FBL26190
crossref_primary_10_1126_sciadv_aaz1580
crossref_primary_10_1182_blood_2017_02_769893
crossref_primary_10_1016_j_ejvs_2023_03_042
crossref_primary_10_1021_acs_molpharmaceut_9b00964
crossref_primary_10_1586_ecp_12_17
crossref_primary_10_3390_molecules21050676
crossref_primary_10_3389_fbioe_2018_00099
crossref_primary_10_1111_1440_1681_12325
crossref_primary_10_1016_j_ijcard_2021_08_051
crossref_primary_10_7759_cureus_69032
crossref_primary_10_1155_2016_4320201
crossref_primary_10_34133_research_0614
crossref_primary_10_1016_j_coph_2012_01_010
crossref_primary_10_1002_14651858_CD012169_pub3
crossref_primary_10_1002_14651858_CD012169_pub2
crossref_primary_10_1111_cbdd_12338
crossref_primary_10_1371_journal_pone_0135692
crossref_primary_10_2147_DDDT_S475838
crossref_primary_10_1111_voxs_12529
crossref_primary_10_1080_09537104_2024_2336093
crossref_primary_10_1016_j_ejphar_2019_172627
crossref_primary_10_1007_s11302_019_09653_6
crossref_primary_10_1161_ATVBAHA_114_304509
crossref_primary_10_1021_acs_chemrev_4c00293
crossref_primary_10_1007_s40138_013_0037_z
crossref_primary_10_1093_bja_aew214
crossref_primary_10_3109_14756366_2014_995180
crossref_primary_10_1016_j_ejps_2022_106157
Cites_doi 10.1080/09537100500063889
10.1074/jbc.M809780200
10.1124/jpet.105.094037
10.2741/2690
10.5414/CPP48259
10.1161/ATVBAHA.110.207522
10.1038/13522
10.1161/01.CIR.103.5.718
10.1111/j.1527-3466.2007.00027.x
10.1055/s-2005-869528
10.1080/09537100802351073
10.1007/s00228-009-0778-5
10.1021/jm981072s
10.1016/0735-1097(88)90158-1
10.1161/CIRCULATIONAHA.109.912550
10.1111/j.1749-6632.2001.tb03521.x
10.1016/S0140-6736(10)61274-3
10.2217/pgs.10.211
10.1016/j.bmcl.2010.05.072
10.1016/j.clinthera.2009.04.017
10.3109/09537104.2011.576284
10.1161/CIRCULATIONAHA.108.833236
10.1111/j.1538-7836.2008.03020.x
10.1161/ATVBAHA.110.219501
10.1111/j.1538-7836.2005.01489.x
10.1161/CIRCULATIONAHA.107.696732
10.1097/MOH.0b013e32832ea2f2
10.2217/fca.10.67
10.1080/09537100701708498
10.1016/j.pharmthera.2010.10.001
10.1056/NEJMoa0904327
10.1160/TH07-11-0673
10.1038/nm.2281
10.1016/j.bmcl.2008.04.028
10.3109/09537104.2010.514967
10.1111/j.1755-5922.2009.00096.x
10.1016/j.jacc.2010.03.100
10.1016/j.thromres.2007.05.020
10.1111/j.1365-2141.2010.08499.x
10.1097/CRD.0b013e3182099d86
10.1055/s-0037-1615596
10.1111/j.1365-2125.2010.03669.x
10.1007/s00392-009-0033-1
10.1056/NEJMoa0908628
10.1160/TH09-06-0418
10.1038/sj.bjp.0704673
10.1021/cb8002094
10.1016/j.bcmd.2005.12.024
10.1016/S0140-6736(96)09457-3
10.3109/09537104.2010.499483
10.1001/jama.2011.332
10.3109/09537101003599549
10.1093/eurheartj/ehp296
10.1161/01.CIR.0000140675.85342.1B
10.1111/j.1538-7836.2007.02775.x
10.1056/NEJMoa0706482
10.1016/S0140-6736(10)61088-4
10.1055/s-0037-1613242
10.1016/S0014-2999(01)00733-6
10.1080/09537100902912451
10.1056/NEJMoa0908629
10.1016/j.jacc.2010.01.062
10.1039/b914375k
10.1055/s-0037-1614133
10.1586/erc.10.90
10.1160/TH09-03-0192
10.1111/j.1538-7836.2009.03527.x
10.3109/09537104.2010.497231
10.1016/S0143-4160(03)00170-2
10.1182/blood.V99.1.193
10.2174/1381612033453947
10.1016/j.ahj.2010.10.036
10.1160/TH10-07-0482
10.1001/jama.2011.290
10.1111/j.1538-7836.2007.02356.x
10.1146/annurev.bi.60.070191.003253
10.1080/09537100120085450
ContentType Journal Article
Copyright 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society
2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.
Copyright © 2011 The British Pharmacological Society 2011
Copyright_xml – notice: 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society
– notice: 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.
– notice: Copyright © 2011 The British Pharmacological Society 2011
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1111/j.1365-2125.2011.03999.x
DatabaseName Wiley-Blackwell Open Access Titles
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1365-2125
EndPage 657
ExternalDocumentID PMC3187865
21518389
10_1111_j_1365_2125_2011_03999_x
BCP3999
Genre reviewArticle
Journal Article
Review
GrantInformation_xml – fundername: Medical Research Council
  grantid: MC_G0900866
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1OC
23N
24P
2WC
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
AOIJS
ATUGU
AZBYB
AZVAB
BAFTC
BAWUL
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FIJ
FUBAC
G-S
G.N
GODZA
GX1
H.X
HF~
HGLYW
HYE
HZI
HZ~
IHE
IPNFZ
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LSO
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
ROL
RPM
RX1
SUPJJ
TEORI
TR2
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WRC
WVDHM
WXI
WXSBR
X7M
XG1
YFH
YOC
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
AAYXX
AEYWJ
AGHNM
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c4739-7563f3c59329e73767f87caee2671817318909b91168d21ab9ce393969b554db3
IEDL.DBID DR2
ISSN 0306-5251
1365-2125
IngestDate Thu Aug 21 18:03:35 EDT 2025
Fri Jul 11 06:05:18 EDT 2025
Mon Jul 21 06:04:07 EDT 2025
Thu Apr 24 23:09:08 EDT 2025
Tue Jul 01 02:29:32 EDT 2025
Wed Jan 22 17:07:17 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4739-7563f3c59329e73767f87caee2671817318909b91168d21ab9ce393969b554db3
Notes http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms
Re‐use of this article is permitted in accordance with the Terms and Conditions set out at
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2125.2011.03999.x
PMID 21518389
PQID 889176208
PQPubID 23479
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3187865
proquest_miscellaneous_889176208
pubmed_primary_21518389
crossref_primary_10_1111_j_1365_2125_2011_03999_x
crossref_citationtrail_10_1111_j_1365_2125_2011_03999_x
wiley_primary_10_1111_j_1365_2125_2011_03999_x_BCP3999
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate October 2011
2011-10-00
2011-Oct
20111001
PublicationDateYYYYMMDD 2011-10-01
PublicationDate_xml – month: 10
  year: 2011
  text: October 2011
PublicationDecade 2010
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: England
PublicationTitle British journal of clinical pharmacology
PublicationTitleAlternate Br J Clin Pharmacol
PublicationYear 2011
Publisher Blackwell Publishing Ltd
Blackwell Science Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: Blackwell Science Inc
References 2010; 56
2010; 11
2010; 103
2006; 36
2002; 99
1991; 60
1999; 42
2011; 12
2008; 6
2011; 17
2009; 119
2011; 19
2009; 158
2001; 103
2001; 85
1996; 348
2011; 153
2010; 66
2010; 21
2010; 20
2011; 129
2009; 98
2002; 88
2003; 9
2004; 35
2005; 31
2011; 22
2001; 936
2007; 5
2009; 361
2009; 284
2009; 120
2001; 12
2011; 161
2010; 30
2001; 412
2009; 16
2007; 25
2009; 15
2010; 6
2010; 8
2009; 20
2011
2010
2002; 135
2008; 18
2008; 19
2009
2011; 31
1988; 11
2008; 13
2008; 99
2006; 316
2008; 121
1999; 5
2009; 27
2011; 105
2007; 357
2004; 110
2009; 30
2010; 48
2011; 305
2007; 116
2009; 31
2010; 376
2000; 84
2009; 102
2009; 7
2005; 3
2009; 4
2005; 16
e_1_2_7_5_2
e_1_2_7_3_2
e_1_2_7_9_2
e_1_2_7_7_2
e_1_2_7_19_2
e_1_2_7_17_2
Oestreich JH (e_1_2_7_73_2) 2010; 11
e_1_2_7_83_2
e_1_2_7_15_2
e_1_2_7_60_2
e_1_2_7_81_2
e_1_2_7_13_2
e_1_2_7_41_2
e_1_2_7_62_2
e_1_2_7_87_2
e_1_2_7_11_2
e_1_2_7_43_2
e_1_2_7_64_2
e_1_2_7_85_2
e_1_2_7_45_2
e_1_2_7_47_2
e_1_2_7_68_2
e_1_2_7_89_2
e_1_2_7_26_2
e_1_2_7_49_2
e_1_2_7_28_2
e_1_2_7_71_2
e_1_2_7_50_2
e_1_2_7_25_2
e_1_2_7_52_2
e_1_2_7_75_2
e_1_2_7_23_2
e_1_2_7_31_2
e_1_2_7_21_2
e_1_2_7_33_2
e_1_2_7_56_2
e_1_2_7_79_2
e_1_2_7_35_2
e_1_2_7_77_2
e_1_2_7_37_2
e_1_2_7_39_2
e_1_2_7_4_2
e_1_2_7_8_2
e_1_2_7_6_2
e_1_2_7_18_2
e_1_2_7_82_2
e_1_2_7_16_2
e_1_2_7_61_2
Bjorkman JA (e_1_2_7_80_2) 2007; 116
e_1_2_7_14_2
e_1_2_7_40_2
e_1_2_7_63_2
e_1_2_7_86_2
e_1_2_7_12_2
e_1_2_7_42_2
e_1_2_7_65_2
e_1_2_7_84_2
e_1_2_7_10_2
e_1_2_7_44_2
e_1_2_7_67_2
Alexander SPH (e_1_2_7_2_2) 2009; 158
e_1_2_7_46_2
e_1_2_7_69_2
e_1_2_7_88_2
e_1_2_7_48_2
e_1_2_7_27_2
e_1_2_7_29_2
Storey RF (e_1_2_7_66_2) 2001; 85
e_1_2_7_72_2
Kowalczyk M (e_1_2_7_54_2) 2009; 15
e_1_2_7_70_2
e_1_2_7_24_2
e_1_2_7_30_2
e_1_2_7_51_2
e_1_2_7_76_2
e_1_2_7_22_2
e_1_2_7_32_2
e_1_2_7_53_2
e_1_2_7_74_2
e_1_2_7_20_2
e_1_2_7_34_2
e_1_2_7_55_2
e_1_2_7_36_2
e_1_2_7_57_2
e_1_2_7_78_2
e_1_2_7_38_2
e_1_2_7_59_2
Butler K (e_1_2_7_58_2) 2010
References_xml – year: 2009
– volume: 5
  start-page: 1199
  year: 1999
  end-page: 202
  article-title: Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1‐deficient mice
  publication-title: Nat Med
– volume: 85
  start-page: 401
  year: 2001
  end-page: 7
  article-title: Open multicentre study of the P2T receptor antagonist ARC69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes
  publication-title: Thromb Haemost
– volume: 13
  start-page: 433
  year: 2008
  end-page: 9
  article-title: Role of P2Y receptor subtypes in platelet‐derived microparticle generation
  publication-title: Front Biosci
– volume: 98
  start-page: 533
  year: 2009
  end-page: 40
  article-title: Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study
  publication-title: Clin Res Cardiol
– volume: 110
  start-page: 1202
  year: 2004
  end-page: 8
  article-title: Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non‐ST‐elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial
  publication-title: Circulation
– volume: 12
  start-page: 443
  year: 2001
  end-page: 7
  article-title: Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood
  publication-title: Platelets
– volume: 88
  start-page: 488
  year: 2002
  end-page: 94
  article-title: Inhibition of ADP‐induced P‐selectin expression and platelet‐leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR‐C69931MX but not aspirin
  publication-title: Thromb Haemost
– volume: 412
  start-page: 213
  year: 2001
  end-page: 21
  article-title: Inhibition of platelet function by administration of MRS2179, a P2Y receptor antagonist
  publication-title: Eur J Pharmacol
– volume: 31
  start-page: 416
  year: 2011
  end-page: 22
  article-title: Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist
  publication-title: Arterioscler Thromb Vasc Biol
– volume: 20
  start-page: 250
  year: 2009
  end-page: 9
  article-title: Measurement of platelet P‐selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin
  publication-title: Platelets
– volume: 121
  start-page: 527
  year: 2008
  end-page: 34
  article-title: Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect
  publication-title: Thromb Res
– volume: 103
  start-page: 718
  year: 2001
  end-page: 23
  article-title: Key role of the P2Y(1) receptor in tissue factor‐induced thrombin‐dependent acute thromboembolism: studies in P2Y(1)‐knockout mice and mice treated with a P2Y(1) antagonist
  publication-title: Circulation
– volume: 66
  start-page: 487
  year: 2010
  end-page: 96
  article-title: Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects
  publication-title: Eur J Clin Pharmacol
– volume: 99
  start-page: 466
  year: 2008
  end-page: 72
  article-title: P2 receptors, platelet function and pharmacological implications
  publication-title: Thromb Haemost
– volume: 103
  start-page: 841
  year: 2010
  end-page: 8
  article-title: Clopidogrel non‐responsiveness and risk of cardiovascular morbidity. An updated meta‐analysis
  publication-title: Thromb Haemost
– volume: 11
  start-page: 1
  year: 1988
  end-page: 11
  article-title: Thrombolysis in Myocardial Infarction (TIMI) Trial‐phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
  publication-title: J Am Coll Cardiol
– volume: 5
  start-page: 2429
  year: 2007
  end-page: 36
  article-title: Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
  publication-title: J Thromb Haemost
– volume: 158
  start-page: S1
  issue: 1
  year: 2009
  end-page: S254
  article-title: Guide to Receptors and Channels (GRAC), 4th edition
  publication-title: Br J Pharmacol
– volume: 361
  start-page: 2330
  year: 2009
  end-page: 41
  article-title: Intravenous platelet blockade with cangrelor during PCI
  publication-title: N Engl J Med
– volume: 11
  start-page: 340
  year: 2010
  end-page: 8
  article-title: Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events
  publication-title: Curr Opin Investig Drugs
– volume: 161
  start-page: 383
  year: 2011
  end-page: 90
  article-title: Comparison of 2 point‐of‐care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention
  publication-title: Am Heart J
– volume: 22
  start-page: 19
  year: 2011
  end-page: 25
  article-title: The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y12 receptor inhibition
  publication-title: Platelets
– volume: 56
  start-page: 185
  year: 2010
  end-page: 93
  article-title: ONSET/OFFSET Investigators. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study
  publication-title: J Am Coll Cardiol
– volume: 116
  start-page: II‐28
  year: 2007
  article-title: AZD6140 inhibits adenosine uptake into erythrocytes and enhances coronary blood flow after local ischemia or intracoronary adenosine infusion
  publication-title: Circulation
– volume: 12
  start-page: 141
  year: 2011
  end-page: 4
  article-title: CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel
  publication-title: Pharmacogenomics
– volume: 120
  start-page: 2577
  year: 2009
  end-page: 85
  article-title: Randomized double‐blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study
  publication-title: Circulation
– volume: 5
  start-page: 577
  year: 2007
  end-page: 82
  article-title: Inhibition of P2Y12 receptor by adenosine diphosphate potentiates the antiplatelet effects of prostacyclin
  publication-title: J Thromb Haemost
– volume: 135
  start-page: 2004
  year: 2002
  end-page: 10
  article-title: 2‐Chloro N(6)‐methyl‐(N)‐methanocarba‐2′‐deoxyadenosine‐3′,5′‐bisphosphate is a selective high affinity P2Y(1) receptor antagonist
  publication-title: Br J Pharmacol
– volume: 21
  start-page: 153
  year: 2010
  end-page: 66
  article-title: The P2X1 ion channel in platelet function
  publication-title: Platelets
– volume: 31
  start-page: 793
  year: 2009
  end-page: 803
  article-title: Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open‐label, crossover study in healthy Korean male subjects
  publication-title: Clin Ther
– volume: 8
  start-page: 1069
  year: 2010
  end-page: 77
  article-title: Update on the clinical development of cangrelor
  publication-title: Expert Rev Cardiovasc Ther
– volume: 31
  start-page: 234
  year: 2005
  end-page: 46
  article-title: Role of CD39 (NTPDase‐1) in thromboregulation, cerebroprotection, and cardioprotection
  publication-title: Semin Thromb Hemost
– volume: 17
  start-page: 110
  year: 2011
  end-page: 6
  article-title: Paraoxonase‐1 is a major determinant of clopidogrel efficacy
  publication-title: Nat Med
– volume: 99
  start-page: 193
  year: 2002
  end-page: 8
  article-title: Adenosine diphosphate (ADP)‐induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors
  publication-title: Blood
– volume: 9
  start-page: 2303
  year: 2003
  end-page: 16
  article-title: ADP receptors‐targets for developing antithrombotic agents
  publication-title: Curr Pharm Des
– volume: 16
  start-page: 159
  year: 2005
  end-page: 70
  article-title: Leukocyte count and leukocyte ecto‐nucleotidase are major determinants of the effects of adenosine triphosphate and adenosine diphosphate on platelet aggregation in human blood
  publication-title: Platelets
– volume: 30
  start-page: 2341
  year: 2010
  end-page: 9
  article-title: Signaling during platelet adhesion and activation
  publication-title: Arterioscler Thromb Vasc Biol
– volume: 6
  start-page: 445
  year: 2010
  end-page: 53
  article-title: Elinogrel: pharmacological principles, preclinical and early phase clinical testing
  publication-title: Future Cardiol
– year: 2011
  article-title: P2Y and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP
  publication-title: Platelets
– volume: 84
  start-page: 891
  year: 2000
  end-page: 6
  article-title: Identification and biological activity of the active metabolite of clopidogrel
  publication-title: Thromb Haemost
– volume: 42
  start-page: 213
  year: 1999
  end-page: 20
  article-title: Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy
  publication-title: J Med Chem
– volume: 284
  start-page: 16108
  year: 2009
  end-page: 17
  article-title: The P2Y12 antagonists, 2‐methylthioadenosine 5′‐monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi‐independent increase in cAMP levels
  publication-title: J Biol Chem
– volume: 35
  start-page: 39
  year: 2004
  end-page: 46
  article-title: Inhibition of ADP‐induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR‐C69931MX and clopidogrel is enhanced by prostaglandin E1
  publication-title: Cell Calcium
– volume: 316
  start-page: 556
  year: 2006
  end-page: 63
  article-title: MRS2500 [2‐iodo‐N6‐methyl‐(N)‐methanocarba‐2′‐deoxyadenosine‐3′,5′‐bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice
  publication-title: J Pharmacol Exp Ther
– year: 2010
  article-title: Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment
  publication-title: J Clin Pharmacol
– volume: 105
  start-page: 96
  year: 2011
  end-page: 106
  article-title: Mode of action of P2Y(12) antagonists as inhibitors of platelet function
  publication-title: Thromb Haemost
– volume: 102
  start-page: 248
  year: 2009
  end-page: 57
  article-title: Mechanisms of platelet activation: need for new strategies to protect against platelet‐mediated atherothrombosis
  publication-title: Thromb Haemost
– volume: 361
  start-page: 1045
  year: 2009
  end-page: 57
  article-title: Ticagrelor versus clopidogrel in patients with acute coronary syndromes
  publication-title: N Engl J Med
– volume: 153
  start-page: 83
  year: 2011
  end-page: 91
  article-title: Extracellular Ca(2+) modulates ADP‐evoked aggregation through altered agonist degradation: implications for conditions used to study P2Y receptor activation
  publication-title: Br J Haematol
– volume: 16
  start-page: 371
  year: 2009
  end-page: 7
  article-title: New P2Y12 antagonists
  publication-title: Curr Opin Hematol
– volume: 20
  start-page: 4104
  year: 2010
  end-page: 7
  article-title: Benzofuran‐substituted urea derivatives as novel P2Y(1) receptor antagonists
  publication-title: Bioorg Med Chem Lett
– year: 2010
– volume: 19
  start-page: 605
  year: 2008
  end-page: 13
  article-title: DG‐041 inhibits the EP3 prostanoid receptor: a new target for inhibition of platelet function in atherothrombotic disease
  publication-title: Platelets
– volume: 22
  start-page: 54
  year: 2011
  end-page: 8
  article-title: P2Y12 receptor in platelet activation
  publication-title: Platelets
– volume: 119
  start-page: 2625
  year: 2009
  end-page: 32
  article-title: Bedside evaluation of thienopyridine antiplatelet therapy
  publication-title: Circulation
– volume: 48
  start-page: 259
  year: 2010
  end-page: 69
  article-title: Pharmacokinetics and the antiplatelet effect of a new clopidogrel formulation, clopidogrel besylate, in healthy subjects
  publication-title: Int J Clin Pharmacol Ther
– volume: 3
  start-page: 2331
  year: 2005
  end-page: 9
  article-title: Adenine nucleotide metabolism in human blood – important roles for leukocytes and erythrocytes
  publication-title: J Thromb Haemost
– volume: 36
  start-page: 223
  year: 2006
  end-page: 7
  article-title: The platelet P2 receptors in arterial thrombosis
  publication-title: Blood Cells Mol Dis
– volume: 15
  start-page: MS24
  year: 2009
  end-page: 30
  article-title: Ticagrelor – a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
  publication-title: Med Sci Monit
– volume: 129
  start-page: 267
  year: 2011
  end-page: 89
  article-title: Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond
  publication-title: Pharmacol Ther
– volume: 376
  start-page: 1320
  year: 2010
  end-page: 8
  article-title: Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
  publication-title: Lancet
– volume: 357
  start-page: 2001
  year: 2007
  end-page: 15
  article-title: Prasugrel versus clopidogrel in patients with acute coronary syndromes
  publication-title: N Engl J Med
– volume: 19
  start-page: 95
  year: 2011
  end-page: 100
  article-title: Ticagrelor: a novel reversible oral antiplatelet agent
  publication-title: Cardiol Rev
– volume: 27
  start-page: 259
  year: 2009
  end-page: 74
  article-title: Ticagrelor: the first reversibly binding oral P2Y receptor antagonist
  publication-title: Cardiovasc Ther
– volume: 7
  start-page: 1556
  year: 2009
  end-page: 65
  article-title: Ticagrelor binds to P2Y receptors independently from ADP but antagonizes ADP‐induced receptor signalling and platelet aggregation
  publication-title: J Thromb Haemost
– volume: 119
  start-page: 3215
  year: 2009
  end-page: 22
  article-title: Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double‐blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study
  publication-title: Circulation
– volume: 6
  start-page: 305
  year: 2010
  end-page: 15
  article-title: Limitations of current therapies to prevent thrombosis: a need for novel strategies
  publication-title: Mol Biosyst
– volume: 30
  start-page: 1964
  year: 2009
  end-page: 77
  article-title: P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use
  publication-title: Eur Heart J
– volume: 60
  start-page: 653
  year: 1991
  end-page: 88
  article-title: Model systems for the study of seven‐transmembrane‐segment receptors
  publication-title: Annu Rev Biochem
– volume: 376
  start-page: 1233
  year: 2010
  end-page: 43
  article-title: CURRENT‐OASIS 7 trial investigators. Double‐dose versus standard‐dose clopidogrel and high‐dose versus low‐dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT‐OASIS 7): a randomised factorial trial
  publication-title: Lancet
– volume: 936
  start-page: 340
  year: 2001
  end-page: 54
  article-title: Platelet‐fibrinogen interactions
  publication-title: Ann NY Acad Sci
– volume: 25
  start-page: 357
  year: 2007
  end-page: 74
  article-title: Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile
  publication-title: Cardiovasc Drug Rev
– volume: 19
  start-page: 134
  year: 2008
  end-page: 45
  article-title: Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti‐thrombotic agents
  publication-title: Platelets
– volume: 305
  start-page: 1136
  year: 2011
  end-page: 7
  article-title: An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial
  publication-title: JAMA
– volume: 21
  start-page: 503
  year: 2010
  end-page: 7
  article-title: Intra‐individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy
  publication-title: Platelets
– volume: 4
  start-page: 115
  year: 2009
  end-page: 26
  article-title: Antagonists of the EP3 receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding
  publication-title: ACS Chem Biol
– volume: 305
  start-page: 1097
  year: 2011
  end-page: 105
  article-title: Standard‐ vs high‐dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial
  publication-title: JAMA
– volume: 18
  start-page: 3338
  year: 2008
  end-page: 43
  article-title: P2Y1 receptor antagonists as novel antithrombotic agents
  publication-title: Bioorg Med Chem Lett
– volume: 56
  start-page: 1456
  year: 2010
  end-page: 62
  article-title: Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy
  publication-title: J Am Coll Cardiol
– volume: 361
  start-page: 2318
  year: 2009
  end-page: 29
  article-title: Platelet inhibition with cangrelor in patients undergoing PCI
  publication-title: N Engl J Med
– volume: 348
  start-page: 1329
  year: 1996
  end-page: 39
  article-title: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
  publication-title: Lancet
– volume: 6
  start-page: 1153
  year: 2008
  end-page: 9
  article-title: The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function
  publication-title: J Thromb Haemost
– ident: e_1_2_7_9_2
  doi: 10.1080/09537100500063889
– ident: e_1_2_7_89_2
  doi: 10.1074/jbc.M809780200
– ident: e_1_2_7_19_2
  doi: 10.1124/jpet.105.094037
– ident: e_1_2_7_14_2
  doi: 10.2741/2690
– ident: e_1_2_7_24_2
– ident: e_1_2_7_45_2
  doi: 10.5414/CPP48259
– ident: e_1_2_7_72_2
– ident: e_1_2_7_11_2
  doi: 10.1161/ATVBAHA.110.207522
– ident: e_1_2_7_15_2
  doi: 10.1038/13522
– ident: e_1_2_7_16_2
  doi: 10.1161/01.CIR.103.5.718
– ident: e_1_2_7_46_2
  doi: 10.1111/j.1527-3466.2007.00027.x
– ident: e_1_2_7_8_2
  doi: 10.1055/s-2005-869528
– ident: e_1_2_7_84_2
  doi: 10.1080/09537100802351073
– ident: e_1_2_7_56_2
  doi: 10.1007/s00228-009-0778-5
– ident: e_1_2_7_65_2
  doi: 10.1021/jm981072s
– ident: e_1_2_7_61_2
  doi: 10.1016/0735-1097(88)90158-1
– ident: e_1_2_7_42_2
– ident: e_1_2_7_51_2
– ident: e_1_2_7_57_2
  doi: 10.1161/CIRCULATIONAHA.109.912550
– ident: e_1_2_7_6_2
  doi: 10.1111/j.1749-6632.2001.tb03521.x
– ident: e_1_2_7_55_2
  doi: 10.1016/S0140-6736(10)61274-3
– ident: e_1_2_7_29_2
  doi: 10.2217/pgs.10.211
– ident: e_1_2_7_64_2
– ident: e_1_2_7_22_2
  doi: 10.1016/j.bmcl.2010.05.072
– ident: e_1_2_7_43_2
  doi: 10.1016/j.clinthera.2009.04.017
– ident: e_1_2_7_75_2
– ident: e_1_2_7_63_2
  doi: 10.3109/09537104.2011.576284
– ident: e_1_2_7_41_2
  doi: 10.1161/CIRCULATIONAHA.108.833236
– ident: e_1_2_7_69_2
  doi: 10.1111/j.1538-7836.2008.03020.x
– ident: e_1_2_7_79_2
  doi: 10.1161/ATVBAHA.110.219501
– ident: e_1_2_7_77_2
  doi: 10.1111/j.1538-7836.2005.01489.x
– ident: e_1_2_7_34_2
  doi: 10.1161/CIRCULATIONAHA.107.696732
– ident: e_1_2_7_48_2
  doi: 10.1097/MOH.0b013e32832ea2f2
– ident: e_1_2_7_74_2
  doi: 10.2217/fca.10.67
– ident: e_1_2_7_20_2
  doi: 10.1080/09537100701708498
– ident: e_1_2_7_30_2
  doi: 10.1016/j.pharmthera.2010.10.001
– ident: e_1_2_7_60_2
  doi: 10.1056/NEJMoa0904327
– volume: 158
  start-page: S1
  issue: 1
  year: 2009
  ident: e_1_2_7_2_2
  article-title: Guide to Receptors and Channels (GRAC), 4th edition
  publication-title: Br J Pharmacol
– ident: e_1_2_7_4_2
  doi: 10.1160/TH07-11-0673
– ident: e_1_2_7_31_2
  doi: 10.1038/nm.2281
– ident: e_1_2_7_21_2
  doi: 10.1016/j.bmcl.2008.04.028
– ident: e_1_2_7_37_2
  doi: 10.3109/09537104.2010.514967
– ident: e_1_2_7_52_2
  doi: 10.1111/j.1755-5922.2009.00096.x
– volume: 15
  start-page: MS24
  year: 2009
  ident: e_1_2_7_54_2
  article-title: Ticagrelor – a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
  publication-title: Med Sci Monit
– ident: e_1_2_7_62_2
  doi: 10.1016/j.jacc.2010.03.100
– ident: e_1_2_7_68_2
  doi: 10.1016/j.thromres.2007.05.020
– ident: e_1_2_7_78_2
  doi: 10.1111/j.1365-2141.2010.08499.x
– ident: e_1_2_7_59_2
  doi: 10.1097/CRD.0b013e3182099d86
– volume: 85
  start-page: 401
  year: 2001
  ident: e_1_2_7_66_2
  article-title: Open multicentre study of the P2T receptor antagonist ARC69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes
  publication-title: Thromb Haemost
  doi: 10.1055/s-0037-1615596
– year: 2010
  ident: e_1_2_7_58_2
  article-title: Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment
  publication-title: J Clin Pharmacol
  doi: 10.1111/j.1365-2125.2010.03669.x
– ident: e_1_2_7_44_2
  doi: 10.1007/s00392-009-0033-1
– ident: e_1_2_7_71_2
  doi: 10.1056/NEJMoa0908628
– ident: e_1_2_7_33_2
  doi: 10.1160/TH09-06-0418
– ident: e_1_2_7_18_2
  doi: 10.1038/sj.bjp.0704673
– volume: 116
  start-page: II‐28
  year: 2007
  ident: e_1_2_7_80_2
  article-title: AZD6140 inhibits adenosine uptake into erythrocytes and enhances coronary blood flow after local ischemia or intracoronary adenosine infusion
  publication-title: Circulation
– ident: e_1_2_7_85_2
  doi: 10.1021/cb8002094
– ident: e_1_2_7_5_2
  doi: 10.1016/j.bcmd.2005.12.024
– ident: e_1_2_7_27_2
  doi: 10.1016/S0140-6736(96)09457-3
– ident: e_1_2_7_32_2
  doi: 10.3109/09537104.2010.499483
– ident: e_1_2_7_40_2
  doi: 10.1001/jama.2011.332
– ident: e_1_2_7_10_2
  doi: 10.3109/09537101003599549
– ident: e_1_2_7_47_2
  doi: 10.1093/eurheartj/ehp296
– volume: 11
  start-page: 340
  year: 2010
  ident: e_1_2_7_73_2
  article-title: Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events
  publication-title: Curr Opin Investig Drugs
– ident: e_1_2_7_28_2
  doi: 10.1161/01.CIR.0000140675.85342.1B
– ident: e_1_2_7_49_2
  doi: 10.1111/j.1538-7836.2007.02775.x
– ident: e_1_2_7_50_2
  doi: 10.1056/NEJMoa0706482
– ident: e_1_2_7_39_2
  doi: 10.1016/S0140-6736(10)61088-4
– ident: e_1_2_7_13_2
  doi: 10.1055/s-0037-1613242
– ident: e_1_2_7_17_2
  doi: 10.1016/S0014-2999(01)00733-6
– ident: e_1_2_7_35_2
  doi: 10.1080/09537100902912451
– ident: e_1_2_7_70_2
  doi: 10.1056/NEJMoa0908629
– ident: e_1_2_7_81_2
  doi: 10.1016/j.jacc.2010.01.062
– ident: e_1_2_7_86_2
  doi: 10.1039/b914375k
– ident: e_1_2_7_25_2
– ident: e_1_2_7_26_2
  doi: 10.1055/s-0037-1614133
– ident: e_1_2_7_67_2
  doi: 10.1586/erc.10.90
– ident: e_1_2_7_7_2
  doi: 10.1160/TH09-03-0192
– ident: e_1_2_7_53_2
  doi: 10.1111/j.1538-7836.2009.03527.x
– ident: e_1_2_7_76_2
  doi: 10.3109/09537104.2010.497231
– ident: e_1_2_7_82_2
  doi: 10.1016/S0143-4160(03)00170-2
– ident: e_1_2_7_12_2
  doi: 10.1182/blood.V99.1.193
– ident: e_1_2_7_23_2
  doi: 10.2174/1381612033453947
– ident: e_1_2_7_36_2
  doi: 10.1016/j.ahj.2010.10.036
– ident: e_1_2_7_88_2
  doi: 10.1160/TH10-07-0482
– ident: e_1_2_7_38_2
  doi: 10.1001/jama.2011.290
– ident: e_1_2_7_83_2
  doi: 10.1111/j.1538-7836.2007.02356.x
– ident: e_1_2_7_87_2
  doi: 10.1146/annurev.bi.60.070191.003253
– ident: e_1_2_7_3_2
  doi: 10.1080/09537100120085450
SSID ssj0013165
Score 2.3232963
SecondaryResourceType review_article
Snippet The P2Y12 receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both...
The P2Y 12 receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both...
The P2Y(12) receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 647
SubjectTerms anti‐platelet
Blood Platelets - drug effects
cangrelor
clopidogrel
Haemostasis Themed Issue
Humans
P2Y12
platelet
Platelet Aggregation - drug effects
Platelet Aggregation Inhibitors - pharmacology
prasugrel
Purinergic P2Y Receptor Antagonists - pharmacology
Thrombosis - prevention & control
ticagrelor
Title Anti‐platelet therapy: ADP receptor antagonists
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2125.2011.03999.x
https://www.ncbi.nlm.nih.gov/pubmed/21518389
https://www.proquest.com/docview/889176208
https://pubmed.ncbi.nlm.nih.gov/PMC3187865
Volume 72
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NTtwwELYKp15KfyhsaZEPFSeySuzEsbltoYi2KooqkLhZsePACpRdsVmJ5dRH6DP2STrjZHdJ4YAQl8hSbMsez3g-2-PPhHyOU146q0zARV4GseUuyHMVBrYwpQStDq3f7_h5LI5O4-9nyVkb_4R3YRp-iMWGG1qGn6_RwHMz6Rq5j9ACD90ycYKvVX3Ek_gD8dEvtjxQiPyrkoiQYe2VRN2gngcr6nqqe_DzfhTlXXTr3dPhGrmcd6yJSrnsT2vTt7f_cT4-T89fk1ctiqWDRu3ekBeuekt2soYGe7ZLT5a3uia7dIdmS4Ls2TsSDap6-Pf3n_EVAF3QG9pcApvt0cFBRmEKduN6dE1hzPPzETL7TtbJ6eHXk_2joH26IbAw-ipIE8FLbhNAh8qlyBhTytTmzjEBzjBKYSZRoTIw0wpZsCg3yjquuBLKAL4pDH9PVqtR5TYJVRIwDuPKhUzFpYG8EWJGSBRF6VjSI-l8mLRtec3xeY0rfWd9A_LSKC-N8tJeXvqmR6JFyXHD7fGIMnSuCRoMEU9X8sqNphMtJax8BQtlj2w0irGoFGGVBGQITe2ozCIDcnx3_1TDC8_1DYJKpYBOCq8Rj26n_rKfYerDUwtukZdsHu4YfSSr9fXUfQL8VZttssLiDL4H335seyv7B8beIqU
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Pb9owFLcqemgvXdd1G_tXHyZOBCUxcezdGFvFWkBoAombFTvOhoYCgiCNnvoR9hn3SfbsBGjGDmjqzVJiy35-z-9n-_n3EHrfDEmiFZcOoVHiNBXRThRx11GxTBhotavseUevTzuj5s04GBfpgMxbmJwfYnvgZizDrtfGwM2BdNnKbYgWuOiCihOcLW8AoDw2Cb7t_uqrv7tS8GxeSYORYfcVeOWwnn-2VPZVewB0P47yIb61Dur6CZpuhpbHpfxorDLZUHd_sT4-0tjP0VkBZHEr17yn6EinF6g2yJmw13U83D3sWtZxDQ92HNnrZ8hrpdnk9_2v-RSwLqgOzt-BrT_g1qcBhlVYz7PZAsO0R99mhtx3eYlG15-H7Y5TZG9wFCgAd8KAkoSoAAAi16EhjUlYqCKtfQr-0AthMeEul7DYUhb7XiS50oQTTrkEiBNL8hxV0lmqXyLMGcAcn3Dt-ryZSPjXM7ARCnGcaD-oonAzT0IV1OYmw8ZUPNjigLyEkZcw8hJWXuJnFXnbmvOc3uOAOnijCgJs0VywRKmerZaCMdj8Ut9lVfQi14xtowZZMQCH0NWSzmx_MDTf5S_p5Lul-wZBhYzCIKlViYP7KT62B6b06n8rXqGTzrDXFd0v_dvX6NTfRD96b1AlW6z0W4BjmXxnzewPQ_kk8A
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9swGLYmkCYuwMZXB9t8QJyaKokTx-bW0VUdX4oQSNys2HEAgdKKptLKiZ-w37hfwmsnbcnKoZq4WUps2a_fj8f268cI7QcRybTi0iE0yZxAEe0kCXcdlcqMgVa7yu53nJ3T3lVwfB1eV_lP5i5MyQ8x3XAzlmH9tTHwQZrVjdxmaEGErpg4IdbyFuDJ5YC6zGh458KfnSh49llJA5Fh8RV69ayeN1uqh6o5_DmfRvka3tr41F1D95ORlWkp961RIVvq6R_Sx_cZ-jparWAsbpd69wl90PlndBCXPNjjJr6cXesaNvEBjmcM2eMN5LXz4u7v85_BAyBdUBxc3gIbH-J2J8bgg_Wg6D9imPTkpm-ofYeb6Kr78_Ko51RvNzgKpp87UUhJRlQI8JDryFDGZCxSidY-hWjoReBKuMsluFrKUt9LJFeacMIplwBwUkm20FLez_UOwpwByPEJ167Pg0zCv54BjVBI00z7YQNFk2kSqiI2N-9rPIhXCxyQlzDyEkZewspL_G4gb1pzUJJ7LFAHTzRBgCWa45Uk1_3RUDAGS1_qu6yBtkvFmDZqcBUDaAhdranM9AdD8l3_kt_dWrJvEFTEKAySWo1YuJ_ix1FsSl_-t-J39DHudMXpr_OTXbTiT1IfvT20VDyO9FfAYoX8Zo3sBcSHI6g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Anti-platelet+therapy%3A+ADP+receptor+antagonists&rft.jtitle=British+journal+of+clinical+pharmacology&rft.au=Wijeyeratne%2C+Yanushi+Dullewe&rft.au=Heptinstall%2C+Stan&rft.date=2011-10-01&rft.pub=Blackwell+Science+Inc&rft.issn=0306-5251&rft.eissn=1365-2125&rft.volume=72&rft.issue=4&rft.spage=647&rft.epage=657&rft_id=info:doi/10.1111%2Fj.1365-2125.2011.03999.x&rft_id=info%3Apmid%2F21518389&rft.externalDocID=PMC3187865
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon